With Q4 Revs Up 124 Percent, Genomic Health In ‘08 Aims to Grow Oncotype Use, Trim Loss | GenomeWeb
Genomic Health this week reported a 124-percent jump in fourth-quarter revenue on strong sales of its Oncotype DX test for breast cancer recurrence, and said it hopes to narrow net loss this year by expanding adoption of the assay.  
"We expect our net loss to narrow in the coming year while we continue to invest in our product pipeline and commercial infrastructure,” Genomic Health President Kim Popovits said during the company’s fourth-quarter conference call this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.